Literature DB >> 3180076

Effects of thioether phospholipid BM 41.440 on protein kinase C and phorbol ester-induced differentiation of human leukemia HL60 and KG-1 cells.

M Shoji1, R L Raynor, W E Berdel, W R Vogler, J F Kuo.   

Abstract

The synthetic thioether phospholipid BM 41.440 (1-S-hexadecyl-2-methoxymethyl-rac-glycero-3-phosphocholine) was found to inhibit protein kinase C (PKC) activity competitively with respect to phosphatidylserine, with an apparent Ki value of about 6.4 microM. The agent also inhibited the enzyme activated by diolein or 12-O-tetradecanoylphorbol-13-acetate (TPA), without affecting binding of [3H]phorbol-12,13-dibutyrate to the enzyme. Myosin light chain kinase and cAMP-dependent protein kinase were not inhibited by BM 41.440, indicating a specificity of the action of the agent. BM 41.440 partly blocked the TPA-induced depletion of soluble PKC in HL60 and KG-1 cells (responsive to the differentiating effect of TPA) but not in K562 cells (resistant to the TPA effect). The thioether inhibited the phosphatidylserine/Ca2+-dependent phosphorylation of several common proteins in the solubilized homogenates of HL60 and KG-1 cells, and that of apparently distinct proteins in the preparation of K562 cells. The TPA-induced differentiation of HL60 and KG-1 cells was inhibited by BM 41.440 at a concentration inhibitory to PKC, but differentiation of HL60 cells promoted by dimethyl sulfoxide, retinoic acid, and 1,25-dihydroxyvitamin D3, on the other hand, was not affected. The present data suggested that PKC inhibition might partly account for the antineoplastic effect of BM 41.440, and that the agent could be useful in studying involvements of the PKC system in cellular processes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3180076

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Radiation-induced activation of transcription factors in mammalian cells.

Authors:  M Krämer; B Stein; S Mai; E Kunz; H König; H Loferer; H H Grunicke; H Ponta; P Herrlich; H J Rahmsdorf
Journal:  Radiat Environ Biophys       Date:  1990       Impact factor: 1.925

2.  Phase I trial of ilmofosine as a 24 hour infusion weekly.

Authors:  M von Mehren; B J Giantonio; C McAleer; R Schilder; J McPhillips; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

3.  Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells.

Authors:  M Shoji; R L Raynor; E A Fleer; H Eibl; W R Vogler; J F Kuo
Journal:  Lipids       Date:  1991-02       Impact factor: 1.880

4.  Cross-resistance pattern of cell lines selected for resistance towards different cytotoxic drugs to membrane-toxic phospholipids in vitro.

Authors:  A W Himmelmann; S Danhauser-Riedl; G Steinhauser; R Busch; E J Modest; A Noseda; J Rastetter; W R Vogler; W E Berdel
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  1-O-Octadecyl-2-O-methylglycerophosphocholine inhibits protein kinase C-dependent phosphorylation of endogenous proteins in MCF-7 cells.

Authors:  X Zhou; G Arthur
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

Review 6.  Cell-signaling targets for antitumour drug development.

Authors:  V G Brunton; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Pharmacological investigations with different protein kinase C inhibitors on IgE-dependent and IgE-independent activation of human basophils.

Authors:  U Amon; E von Stebut; H H Wolff
Journal:  Agents Actions       Date:  1993-05

8.  Cytotoxicity of ether phospholipid BM 41.440 on neuroblastoma cells.

Authors:  R Girgert; P Schweizer; I Bock; R Narr; G Bruchelt
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

9.  Antitumor activity of Ilmofosine (BM 41.440) in the 3Lewis-lung carcinoma model.

Authors:  D B Herrmann; H G Opitz; P G Munder
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

Review 10.  Membrane-interactive lipids as experimental anticancer drugs.

Authors:  W E Berdel
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.